Compounds > suberoylbisphosphonic acid
Page last updated: 2024-12-10

suberoylbisphosphonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

suberoylbisphosphonic acid: structure given in first source; inhibits hydroxyapatite formation, dissolution in vitro, and the calcification of bioprosthetic tissue implanted subdermally in rats [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3035700
SCHEMBL ID9314749
MeSH IDM0201529

Synonyms (8)

Synonym
suberoylbisphosphonic acid
(8-oxo-8-phosphonooctanoyl)phosphonic acid
(1,8-dioxo-1,8-octanediyl)bisphosphonic acid
139339-85-8
phosphonic acid, (1,8-dioxo-1,8-octanediyl)bis-
subp
SCHEMBL9314749
DTXSID40161023

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Consequently, main pharmacokinetic parameters (AUC, CL, and V(ss)) were influenced by the mode of drug administration, precluding accurate determination of bioavailability from AUC values."( Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination.
Ezra, A; Golomb, G; Hoffman, A; Stepensky, D; Van Gelder, JM, 2001)		0.31

Bioavailability

ExcerptReferenceRelevance
" Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue."( The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model.
Binderman, I; Breuer, E; Golomb, G; Yaffe, A, 2000)		0.31
" Consequently, main pharmacokinetic parameters (AUC, CL, and V(ss)) were influenced by the mode of drug administration, precluding accurate determination of bioavailability from AUC values."( Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination.
Ezra, A; Golomb, G; Hoffman, A; Stepensky, D; Van Gelder, JM, 2001)		0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's2 (28.57)29.6817
2010's0 (0.00)24.3611
2020's3 (42.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
alendronate
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.		2101,1-bis(phosphonic acid);
primary amino compound		bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
etidronate
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.		2101,1-bis(phosphonic acid)antineoplastic agent;
bone density conservation agent;
chelator
pamidronate
[no description available]		2.420phosphonoacetic acid
substance p
[no description available]		2.610peptideneurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent
neurokinin a
Neurokinin A: A mammalian neuropeptide of 10 amino acids that belongs to the tachykinin family. It is similar in structure and action to SUBSTANCE P and NEUROKININ B with the ability to excite neurons, dilate blood vessels, and contract smooth muscles, such as those in the BRONCHI.		2.610
neuropeptide y
Neuropeptide Y: A 36-amino acid peptide present in many organs and in many sympathetic noradrenergic neurons. It has vasoconstrictor and natriuretic activity and regulates local blood flow, glandular secretion, and smooth muscle activity. The peptide also stimulates feeding and drinking behavior and influences secretion of pituitary hormones.		2.610
chitosan
[no description available]		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Degenerative Disc Disease
[description not available]		03.0120
Innate Inflammatory Response
[description not available]		02.610
Ache
[description not available]		03.0120
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.610
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		03.0120
Intervertebral Disc Degeneration
Degenerative changes in the INTERVERTEBRAL DISC due to aging or structural damage, especially to the vertebral end-plates.		03.0120
Pain, Chronic
[description not available]		02.610
Bone Stress Reaction
[description not available]		02.610
Chronic Pain
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.		02.610
Bone Loss, Osteoclastic
[description not available]		01.9910
Calcification, Pathologic
[description not available]		02.3920
Calcinosis
Pathologic deposition of calcium salts in tissues.		02.3920
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		0210
Alveolar Bone Atrophy
[description not available]		0210
Cardiomyopathies, Primary
[description not available]		01.9810
Cardiomyopathies
A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).		01.9810